Polymer Based Therapies for the Treatment of Chronic Pain by Pradeep K. Dhal et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Polymer Based Therapies  
for the Treatment of Chronic Pain 
Pradeep K. Dhal, Diego A. Gianolio and Robert J. Miller* 
Drug and Biomaterial R&D 
Genzyme Corporation – A Sanofi Company, Waltham, MA, 
 USA 
1. Introduction 
Since chronic pain manifests functional limitation, it is the leading cause of longer term 
disability [1, 2]. In the US alone, an estimated 75 million people suffer from chronic pain [3]. 
In addition to chronic pain, proper management of postoperative acute pain impacts the 
clinical outcome of patients undergoing surgery [4]. Opioid family of analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs) are the main stays of current pharmacological 
agents available for the management of chronic pain [5, 6]. However, current therapies for 
pain management show modest efficacy and are associated with significant side effects. The 
major adverse effects of oral NSAIDs are gastrointestinal bleeding, gastric ulcer, renal 
failure and cardiovascular risks (in particular with selective COX-2 inhibitors) [7, 8]. The 
side effects of opioid family therapies include constipation, nausea, cognitive impairment 
and most importantly addiction [9, 10]. Thus, development of safer and effective treatment 
of chronic pain is an important goal of current pharmaceutical research. 
In recent years numerous efforts have been made to develop long-acting opioid analgesics 
and NSAIDs to modulate their pharmacokinetic profiles. Some of these include sustained 
release formulations and topical gels [11, 12]. Biological agents such as antibody against 
nerve growth factor (NGF) have also been evaluated as therapies for chronic pain. The anti-
NGF antibody acts by sequestering NGF and thus inhibits its interaction with the NGF-
receptor on the sensory neurons [13].  
Polymeric approach offers an attractive route to develop novel therapeutic agents for effective 
management of chronic pain. Interesting physical and chemical characteristics of synthetic and 
natural polymers enable them as promising materials for biomedical applications such as 
therapeutic agents, drug delivery carriers, and medical devices [14, 15]. A number of polymer 
derived therapies have been commercialized in the marketplace [16, 17]. The present article 
reviews the current state of research and development efforts to discover and develop 
biomedical polymer as therapeutic agents for the treatment of chronic pain. While use of 
polymer-derived agents for the treatment of different kinds of pains will be highlighted, the 
primary focus of the present article pertains to management of pain arising from osteoarthritis. 
Furthermore, role of polymers as intrinsically pain relieving agents either alone or as chemical 
conjugates of low molecular weight pain modulating agents are described in this article. The 
research and development efforts to develop control release formulations of low molecular 
weight pain therapies are outside the scope of this article. There are in fact a number of 
interesting articles that describe this aspect of pain management therapies [18, 19].  
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2. Osteoarthritis pain 
Osteoarthritis (OA) is one of the most prevalent musculo-skeletal degenerative diseases [20]. 
Although OA affects joints of the knee, hip, hand, and spine, knee is the most affected joint 
[21]. As a result of pain and reduced mobility, OA leads to significant loss of quality of life. 
Since OA is generally considered to be a result of mechanical “wear and tear” of joints, it 
typically affects people over the age of 60. However, its onset can be expedited at younger 
age due to other factors including obesity, genetic factors, and joint injury [22, 23]. 
Approximately 10% of the world’s adult population over the age of 60 has been affected by 
OA [24]. Therefore, the economic burden of this disease, which includes healthcare costs 
and loss of productivity, is significant. These expenditures are likely to escalate with aging 
population. At present approximately 27 million people in the US suffer from OA and it has 
been estimated that by the year 2030 25% of the US adult population (a third of which of 
working age) will be affected by OA [25]. 
Although OA manifests a broad clinical syndrome, its primary cause has been attributed to 
the progressive breakdown of articular cartilage and chondrocytes within the synovial 
joints. This degeneration leads to narrowing of the joint space, suchondral sclerosis, and 
synovial inflammation. Breakdown of the cartilage results in alternation in joint mechanics, 
which further exacerbates the disease [26, 27]. In OA, concentrations of a number of 
mediators of inflammation such as cytokines, chemokines, and proteolytic enzymes like 
matrix metalloproteinases (MMPs) as well as free radicals are elevated in the synovial fluid 
that catalyze further degradation of cartilage [28, 29]. This process results in a self-sustaining 
degenerative circle that hinders the natural process of cartilage repair. 
In spite of years of intensive research in tissue engineering, there has been no breakthrough 
to regenerate physiologically viable articular cartilage [30]. Also, no therapeutic agent has 
been developed that demonstrates structure modifying efficacy in OA patients [31]. The 
current therapies for OA are largely symptomatic in alleviating the chronic pain. These 
agents largely include anti-inflammatory agents, NSAIDs, and opioid family of analgesics. 
The relative efficacies of these therapies to relieve OA associated chronic pain have been 
modest at best [32, 33]. As mentioned earlier, long term use of these pharmacological agents 
results in major side effects (see above). In order to minimize systemic side effects associated 
with oral NSAIDs, topical agents containing the active agents have been developed. These 
delivery systems are expected to deliver the drugs in high concentrations locally and would 
reduce systemic side effects [34]. However, efficacy of these topical therapies is modest. In 
recent years, other novel therapeutic approaches for the management of OA pain has been 
pursued that include antibodies targeting NGF and antagonist of Transient Receptor 
Potential Vanilloid (TRPV) family of ion channels [35, 36]. One of the attractive therapeutic 
options for treating OA associated pain are polymer based viscosupplements. The following 
section describes the state of viscosupplement based treatments for OA pain.  
3. Hyaluronic acid derived viscosupplements 
3.1 Hyaluronic acid and its biology 
Hyaluronic acid or hyaluronan (HA) is a polysaccharide that belongs to the 
glycosaminoglycan class of biological macromolecules. This highly viscous anionic 
biopolymer is composed of -1, 3-D-glucuronic acid and -1, 4-N-acetyl-D-glucosamine 
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arranged in an alternate fashion along the polymer backbone (Fig. 1). HA is ubiquitous in 
nature and is produced by every tissue of higher organisms and some bacteria. The 
biopolymer is found in the extracellular matrices (particularly in soft connective tissues), 
synovial fluid, and cartilage. HA is endogenously synthesized by chondrocytes and 
synoviocytes [37-39]. After being released into the synovial space, HA accumulates on the 
surfaces of cartilage and ligament. Endogenously synthesized HA is generally of very 
high molecular weight (in the range of 3 -5 million Dalton) and its fully hydrated form 
assumes a globular shape [40]. Unique viscoelastic properties of HA enables it to maintain 
rheological homeostasis of the synovial fluid in the joints and plays a critical role in 
providing lubrication, elasticity, and shock absorption to joint tissues. Furthermore, by 
providing a coat on the surface of articular cartilage, HA protects the cartilage and blocks 
the loss of proteoglycan from the cartilage matrix into the synovial space [41]. In healthy 
joint of human knee, the normal concentration of HA in the synovial fluid is in the range 
of 2.5 - 4.0 mg/mL. However, under pathological conditions such as osteoarthritis, the 
concentration of HA is significantly reduced (estimated to be ~ 1 - 2 mg/mL) [42]. 
Furthermore, the biopolymer undergoes degradation under diseased conditions with 
substantial reduction in molecular weight. A combination of lowering in concentration 
and molecular weights leads to lowering in viscosity and elasticity of synovial fluid and 
consequently adverse impact on joint function. Thus, catabolic degradation of HA directly 
correlates with the onset OA. 
 
 
Fig. 1. Chemical structure of hyaluronic acid. 
3.2 HA derivatives for the treatment of osteoarthritis 
In addition to acting as a lubricant for the joint, HA has been reported to impart anti-
inflammatory, anabolic, and chondroprotective effects [43, 44]. Since OA onset is attributed 
to degradation of high molecular weight HA and its concentration in the synovial fluid, 
increase in HA concentration either by increasing the rate of the proteoglycan biosynthesis 
or by incorporating HA exogenously to the joint space would improve joint function and 
relieve OA associated chronic pain. Therefore, the effect of intraarticular administration of 
exogenous HA to restore rheological properties of the synovial fluid have been extensively 
studied [45]. 
In order to maintain desired viscoelastic property of synovial fluid, the exogenous HA 
needs to have high molecular weight. It has been observed that the frequency and the 
amount of exogenous HA injected can be lowered by increasing the molecular weight of HA 
based exogenous viscosupplement. Towards that end, a variety of synthetic approaches 
have been undertaken to engineer high molecular weight HA derivatives [46]. In general, 
the desired rheological properties of HA based viscosupplements are achieved by 
crosslinking of naturally occurring linear HA to produce higher molecular weight 
compounds. 
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Functional group richness of HA has rendered it to be an important precursor material for 
the design and synthesis of numerous biomaterials with tuned physicochemical and 
biological properties that have found broad applications in biomedicine and biosurgery [47, 
48]. HA offers three kinds of functional groups that can be used for chemical modification: 
carboxylic acid, primary and secondary hydroxyl, and N-acetyl (after removal of acetyl 
group to generate primary amine). While carboxyl groups can be modified to introduce 
amide and ester bonds, the hydroxyl groups can be subjected to reaction with various 
electrophiles such as epoxides, alkyl halides, alkyl tosylates, vinyl sulfones, etc. However, 
since HA is unstable at low pH, the chemical reactions employed for its modification must 
be selected very carefully so that they are mild and compatible to HA. This is necessary to 
avoid undesired degradation of HA to lower molecular weight. Furthermore, the 
byproducts of these reactions must be benign for both short- and long-term uses. Over the 
years, a great deal of research efforts have been put forth to synthesize chemically modified 
HA [49]. 
In order to synthesize HA derived viscosupplements, linear HA has been subjected to 
crosslinking reactions with a number of bifunctional reagents such as diepoxides, divinyl 
sulfone, epichlorohydrin etc [50, 51]. Some representative examples of crosslinking 
chemistries that were carried out to prepare HA based hydrogels are shown in Figure 2.  
 
 
Fig. 2. Representative examples of crosslinking chemistries used to prepare HA hydrogels. 
Several factors need to be taken into consideration while optimizing HA derived 
viscosupplementation products. For example, the rheological properties need to be tuned 
so that they match with those of native synovial fluid. The hydrogels must be free from 
any reagents that could trigger an inflammatory response associated with an exogenous 
material. The molecular weight of the hydrogel is critical to obtain desired clinical benefits 
since HA is prone to degradation and this process is accelerated in a diseased joint. A 
variety of HA derived crosslinked viscosupplements have been approved for human use. 
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The precursor HA for these preparations are obtained either from avian sources or by 
biofermentation in bacteria. Table 1 summarizes some important features of 
representative HA based viscosupplements that are marketed for intraarticular injection 
in the knee to relieve OA pain [52]. Particularly, these products differ by their molecular 
weights, which influence their rheological properties and hence residence time in the 
joint.  
 
 
Brand name Generic name HA source 
Modification 
type 
Molecular 
weight (kDa) 
Artz/Supartz Sodium 
hyaluronate 
Avian N/A 600 – 1,200 
Euflexxa Sodium 
hyaluronate 
Biofermentation N/A 2,400 – 3,600 
Hyalgan Sodium 
hyaluronate 
Avian N/A 500 - 730 
Intragel Sodium 
hyaluronate 
Biofermentation N/A 800 – 1, 200 
Orthovisc High mol. Wt. 
hyaluronan 
Biofermentation 
Chemical 
Modification 
1,100 – 2,900 
Synvisc Hylan G-F 20 Avian Cross-linked 6,000 
Table 1. Representative examples of clinically approved hyaluronic acid (HA) based 
viscosupplementation products (reference 45). 
One of the most effective viscosupplement that has been approved for clinical use is 
Synvisc (Hylan G-F 20) and its single injection formulation, Synvisc-One [53]. The 
main components of Synvisc are HA lightly crosslinked with formaldehyde (Hylan A) 
and divinyl sulfone crosslinked hylan A (Hylan B). Synvisc contains 90% (v/v) of Hylan 
A and 10% (v/v) of hylan B and its chemical structure is shown in Figure 3. Synvisc has 
been approved for the treatment of pain associated with mild to moderate OA. In 
subsequent clinical studies it has been observed that intraarticular injection of Synvisc 
resulted in significant pain relief in the carpometacapal joint, temporomandibular joint 
and the hip [54]. These findings suggest that pain relief from the intraarticular injections 
of HA-derived viscosupplements is not limited to knee. Since, OA of the hip is the second 
most common form of arthritis after OA of the knee, additional clinical investigation of 
the role of viscosupplements in relieving chronic pain arising from hip arthritis is 
warranted. 
The biological mechanisms underlying the pharmacological action of HA derived 
viscosupplements to relieve OA pain are not completely understood. It was initially 
thought that since there is a reduced level of HA in OA joints, intraarticular injection of 
exogenous HA restores the rheological properties of synovial fluid to the level present in 
healthy joints. However, while the half-life of exogenous HA in the synovial fluid is only 
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few days, its clinical effect in reducing OA pain has been found to be maintained for 
several months [55]. This indicates that mechanism of action of HA derived 
viscosupplements is of multifactorial nature and is a combination of physical and 
biological effects. A number of in vitro studies have been carried out to investigate the 
biological activities of HA [56]. The results of these studies suggest that HA exhibits 
chondroprotective and anti-inflammatory effects in the synoviocytes by preventing 
invasion of inflammatory cells to the joint space. Biological activity of HA has also been 
attributed to down regulation of the gene expression of various inflammatory cytokines 
and catabolic enzymes like aggrecanase. Furthermore, being a natural ligand of the cell 
surface receptor CD44, HA has been thought to impart its effect by modulating CD44-
mediated metabolism. In another in vitro study, when synovial fibroblasts were cultured 
with high molecular weight HA, newly synthesized HA molecules were found. These 
biological effects of exogenous HA may result in overall cartilage protection [57, 58]. 
Thus, well controlled clinical studies would shed further light on the chondro-protection 
properties of exogenous HA like Synvisc and lead to the discovery of novel therapies with 
disease modifying properties. 
 
 
 
Fig. 3. Structure of Hylan B component of Synvisc. 
3.3 HA-steroid combinations for the treatment of chronic pain 
One of the shortcomings of HA derived viscosupplements is their slower onset of action 
to reduce OA pain relative to low molecular weight drugs such as NSAIDs and steroids. 
Therefore, the viscosupplements are generally administered weekly over a course of three 
to five weeks. As described earlier, unlike traditional pain killers, pain relief from 
viscosupplements lasts much longer (up to several months). Although intraarticular 
injection of corticosteroids achieves maximum benefit within few days of injection, 
www.intechopen.com
 
Polymer Based Therapies for the Treatment of Chronic Pain 
 
33 
repeated injection of these catabolic agents can have adverse effect [59]. In order to 
achieve fast and longer lasting pain relief while minimizing the side effects of steroids, 
combination therapy of HA and corticosteroids have been envisioned. Non-covalently 
bound admixtures of HA gel with steroids, where the steroid is dispersed within the HA 
hydrogel matrix have been investigated as combination therapy to treat OA pain. This 
approach allows sustained local delivery of the steroid at OA site and would overcome 
the side effects associated with steroid overdose. Figure 4 shows the structures of 
representative corticosteroids that have used to prepare HA derived drug-
viscosupplement composites. 
 
 
 
Fig. 4. Corticosteroids used to prepare HA-steroid composite hydrogel  
viscosupplements. 
Preparation stable formulation of crosslinked HA hydrogel, Synvisc with triamcinolone 
hexaacetonide (TAH) (Figure 4, 1) was investigated by dispersing Tween-80 stabilized TAH 
colloidal suspension within a swollen gel of Syvisc [60]. By optimizing the ratio of 
Synvisc to TAH in the formulation mixture, a stable composite was obtained. The 
rheological properties of Synvisc were not adversely affected by the presence of the 
hydrophobic corticosteroid and the composition was found to be stable in an accelerated 
shelf life test.  
Another steroid-viscosupplement composite was prepared by crosslinking linear HA in the 
presence of triamcinolone acetonide (Figure 4, 2). In this study, divinyl sulfone was allowed 
to react partially with HA to generate a linear HA structure with pendant vinyl sulfone 
group. To a solution of this vinyl sulfone functionalized HA was added a suspension of 2 
and resulting reaction mixture was treated with ,-dithio polyethylene glycol (PEG)  
as the crosslinking agent. A crosslinked HA gel with relatively homogeneously distributed 
steroid particles within the gel matrix was obtained. The synthetic strategy adopted for  
the preparation of this dual-acting viscosupplement is shown in Figure 5 [61]. In a 
preliminary clinical study, this steroid-HA composite (Hydros-TA) showed faster pain relief 
compared to the corresponding native viscosupplement alone. Long term clinical  
study involving larger patient population needs to be carried out to demonstrate the clinical 
efficacy of such steroid-viscosupplement composites to treat OA associated chronic  
pain.  
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Fig. 5. Crosslinking of HA in the presence of a dispersion of triamcinolone acetonide to 
prepare viscosupplment-steroid composite hydrogel 
3.4 Covalent conjugates of HA and low molecular pain killers 
Intrinsic biocompatibility and its versatility for chemical modification make HA  
an attractive biomaterial to synthesize conjugated drug delivery systems. Chemical 
modification of HA has allowed the preparation of an array HA-drug conjugates and  
HA-protein conjugates as sustained-release carriers for drugs and biotherapeutics [62, 63]. 
Covalent conjugates of HA containing hydrogels with pain relieving agents have  
been explored as dual acting agents to treat chronic pain. This approach would offer a 
number of potential clinical benefits, that include: i) retaining viscosupplementation 
property of soluble HA, ii) minimizing the systemic exposure of NSAIDs and opioid 
family pain killers by localizing administration to the target site, iii) modulating the 
duration of action of these pain killers by incorporating appropriate conjugation 
chemistry to control the rate of cleavage of the drug from the HA gel, and iv) minimizing 
the frequency of administration of viscosupplement and the pain killer in the clinic. These 
features of the HA-drug conjugates could lead to better patient compliance and improved 
quality of life. 
A series of HA derived functional hydrogels conjugated with local analgesics (e.g. 
bupivacaine) and opioid drugs (e.g. morphine) were synthesized in our laboratories as 
long acting treatments for chronic pain [64, 65]. Divinyl sulfone crosslinked HA hydrogel 
(Hylan B) was used as the polymer matrix for the synthesis of these drug conjugates. 
Appropriate linker arms were designed to tether these pain relieving agents to the HA 
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matrix. Bupivacaine was conjugated to HA through a hydrolysable imide bond (Figure 
6A). On the other hand, opioid drugs such as morphine, naloxone analogs were 
conjugated via a hydrolysable ester bonds (Figure 6B). A number of conjugates were 
synthesized by varying the nature of the linker arm, spacer length, and the amount of the 
drug loading. A systematic evaluation of the release kinetics of the drugs from the HA gel 
was carried out under in vitro conditions to identify an optimum composition. The 
optimum drug-HA conjugate from each class was evaluated in vivo for its biological 
activity. These drug-conjugated HA hydrogels exhibited therapeutic benefits by 
prolonging pain relief and were more effective than the individual agents and their 
admixtures. These preclinical research findings suggest that development of HA based 
viscosupplements conjugated with traditional pain relieving agents might lead to a 
promising new generation of long acting therapies for the treatment of OA associated 
chronic pain. 
 
 
 
Fig. 6. HA conjugated local analgesics (A) and opioids. 
In related work, conjugates of HA with methotrexate (MTX) were synthesized to achieve 
viscosupplementation and anti-inflammatory effect concurrently intraarticularly [66]. 
Increased levels of TNF- have been found in the synovium of OA affected joints that can be 
mitigated by oral administration of MTX [67]. However, systemic administration of MTX is 
associated with certain side effects such as pneumonitis and myelosuppression [68]. 
Therefore, by localizing MTX to target joint by delivering it as a polymer conjugate, the 
systemic side effect could be minimized. After a careful structure-activity study by 
screening various linker arms and enzyme target groups, an optimized HA conjugate of 
MTX was identified (Figure 7). A peptiditic linker was chosen as target for cathepsin 
enzymes, which are over-expressed in OA joints. The polyethyleneglycol (PEG) linker was 
chosen to enable the peptide target to be accessible to the cathepsin enzyme in the joint 
environment. In vitro and in vivo studies revealed that the HA-MTX conjugate is capable of 
reducing joint pain and swelling of the knee. On the other hand, admixture of HA and MTX 
showed marginal efficacy. 
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Fig. 7. HA conjugate of methotrexate as an intraarticular combination therapy for the 
treatment of OA pain. 
4. Polymer-opioid conjugates and polymeric opioid derivatives 
Besides being a first-line analgesic therapy for acute pain, opioids have been found to be 
useful in treating chronic pain. However, the adverse effects associated with their long term 
use limit the therapeutic benefits of opioid analgesics, thus leading to discontinuation of the 
therapy. Constipation (opioid-induced bowel dysfunction (OBD)) is one of the significant 
side effects associated with opioid therapies. OBD affects up to 80% of the patients 
undergoing opioid therapy. While other side effects associated with chronic use of opioids 
resolve with time, constipation continues to persist [69]. 
Efforts have been made to utilize polymeric approach to design and develop new generation 
of opioid analogs as pain killers. These polymeric compounds enable the patients to 
overcome OBD without losing the benefits of opioid therapy by limiting drugs’ systemic 
absorption. Pegylation chemistry was utilized to synthesize these macromolecular opioids. 
The technology of pegylation has been successfully utilized to improve pharmacokinetic 
properties of a number of (bio)pharmaceutical agents [70]. Two representative polymer 
conjugated opioid derivatives are shown in Figure 8. These compounds consist of naloxol 
analogs linked to PEG chains through hydrolytically stable ether linkage [71, 72]. In 
preclinical studies, these pegylated opioid derivatives were found to maintain their centrally 
mediated analgesia, while antagonizing peripherally mediated constipation. One of the key 
conjugates, NKTR-118 (Figure 8A, n = 7) has proceeded to advanced clinical trial. In the 
phase II clinical trial, patients receiving NKTR-118 exhibited significant increase in bowel 
movement compared to patients receiving native naloxol, without compromising the 
analgesic property of the opioid [73]. NKTR-118 is currently undergoing phase III clinical 
trial. 
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Fig. 8. Polymer modified naloxol derivatives to prevent opioid induced constipation. 
Another interesting approach to develop polymeric pain relievers has been reported that 
utilizes a polymerization chemistry to synthesize poly(anhydride-esters), where the 
bioactive drug becomes part of the polymer backbone [74]. The general structure of this 
class of polymeric pain relievers is shown in Figure 9. Following this strategy, they were 
able to incorporate significant amounts (~ 62%) of the deliverable drug to the polymer chain. 
Hydrolytic degradation of these poly(anhydride-ester) polymers under physiological pH 
conditions releases the drug in a controlled manner. As a result, the side effects associated 
with the native drug (if released immediately) can be minimized. Some of the polymeric 
pain relievers reported are poly(anhydride-esters) containing the anti-inflammatory agent, 
salicylic acid and the opioid drug, morphine (Figure 10). Although syntheses of polymeric 
pain relievers based on these poly(anhydride-ester) scaffolds have been studied extensively, 
there is limited information about the biological activities of these polymers as treatments 
for chronic pain [75, 76]. Nevertheless, these polymeric opioids and anti-inflammatory 
agents offer a new perspective to develop novel treatments for chronic pain. 
 
 
Fig. 9. Structure of salicylic acid-based poly(anhydride-esters) as polymeric anti-
inflammatory agents. 
 
 
Fig. 10. Structure of morphine-based poly(ester-anhydride). 
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5. Conclusion 
Because of its clinical relevance, development of novel pharmacologic agents for effective 
management of chronic pain continues to be an important goal of pharmaceutical research. 
Although numerous therapeutic agents with different modes of action have been developed 
to treat chronic pain, no single agent exhibits the most desired profile. For example, while 
opioids and NSAIDs remain the main stay of therapeutic options, concerns over their 
associated side effects have begun to limit their use. Polymeric approach offers a variety of 
options to develop a new generation of pain relievers, which include intrinsically bioactive 
polymers to different delivery systems for traditional pain killers. HA derived 
viscosupplements offer an attracting option to treat chronic pain due to excellent 
biocompatibility and various biological functions of HA. The ability to trigger various 
biological functions makes HA based viscosupplements as promising agents to not only 
relieve symptomatic effects of chronic OA pain, but also to bring about potentially disease 
modifying effects. Therapies comprising of polymers in combination with traditional pain 
killers (either as conjugates or as stable non-covalent formulations) have been found to 
minimize the side effects of the latter. By targeting the disease via different mechanisms of 
actions, these combination agents could become superior therapeutic options to treat 
chronic pain. With increasing understanding of the pathobiology of chronic pain and intense 
research in biomedical polymers, it will be possible to develop novel polymer based 
therapies in the near future that are safe and could act as structure modifying treatments for 
chronic pain.  
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